For the year ending 2025-12-31, LONA had $20,838K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -105,609 |
| Non-cash consideration for acquired in-process research and development | 67,659 |
| Change in fair value of sermonix pre-funded warrant | 4,579 |
| Stock-based compensation | 6,102 |
| Depreciation expense | 972 |
| Non-cash lease expense | 273 |
| Amortization of premiums and accretion of discounts on available-for-sale securities, net | 329 |
| Prepaid expenses and other current and long-term assets, net | -2,439 |
| Accounts payable and accrued liabilities | -21,342 |
| Operating lease liability | -414 |
| Other long-term liabilities | -59 |
| Net cash used in operating activities | -45,729 |
| Purchases of available-for-sale securities | 37,643 |
| Maturities of available-for-sale securities | 21,749 |
| Net cash (used in) provided by investing activities | -15,894 |
| Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan | 37 |
| Proceeds from pipe financing | 89,991 |
| Issuance costs from pipe financing | 7,567 |
| Net cash provided by financing activities | 82,461 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 20,838 |
| Cash, cash equivalents and restricted cash, beginning of period | 49,069 |
| Cash, cash equivalents and restricted cash, end of period | 69,907 |
LeonaBio, Inc. (LONA)
LeonaBio, Inc. (LONA)